Purpose | Irreversible cathepsin B inhibitor. Does not bind to or inhibit any of the caspases |
Sequence | Biotin-Phe-Ala-CH2F |
Specificity | Specifically binds to and inhibits Cathepsin B. Does not bind to or inhibit any of the caspases. |
Characteristics |
Trifluoroacetic acid salt of the fluoromethyl ketone biotinylated peptide inhibitor of Cathepsin B (Caspase inhibitor negative control). The CH2F (fluoromethyl ketone) inhibitor has several advantages over other types of derivatives: - Penetrates cell membranes - Not toxic to cells - Irreversible inhibition The ten known caspases are involved in theproteolytic cascade that results in apoptosis andin the maturation process of IL-1? necessary forinflammation. The use of biotinylated FMK-typeinhibitors for various caspases requires abiotinylated FMK-type inhibitor that does notaffect caspases as a negative control. TheBiotin-FA-FMK does not inhibit the activity ofcaspases in intact cells and does not block theinduction of apoptosis as caspase inhibitors do.It can, therefore, be used as a negative controlfor the FMK moiety of the biotinylated caspaseinhibitor, both in vivo and in vitro. |
Solubility | DMSO |
Molecular Weight | 478 Da |
Application Notes | Irreversible binding to and inhibition of Cathepsin B. The second order rate constant (k2) of inactivation for human liver Cathepsin B is 1,220 M -1 s -1 , determined from the observed rate of inactivation (k) divided by the inhibitor concentration (I): k2 = k/I. Serves as a negative control in studies using the biotinylated FMK-containing caspase inhibitors. |
Comment |
Dissolve Biotin-FA-FMK in high purity (>99.9%) DMSO before use. |
Restrictions | For Research Use only |
Format | Solid |
Storage | RT |